HOME > BUSINESS
BUSINESS
- Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
- US Consulting Firm Says New Forecast Will Be Necessary for Anticancer Drug Market
December 6, 2011
- Taiho to Cooperate in Doctor-Led Clinical Trial
December 6, 2011
- Takeda Sets Up Global Vaccine Business Company to Enhance Global Operations
December 6, 2011
- OncoTherapy Confirms Safety of Cancer Vaccine OCV-105 in PI Trial
December 6, 2011
- Eisai’s US Research Subsidiary Starts Full Operation
December 5, 2011
- Pfizer, MSD Issue Repeated Warnings for Improper Use of Pneumococcal Vaccines Prevnar, Pneumovax
December 5, 2011
- Teijin Pharma Gets Good Response for Feburic from Medical Institutions: President Arao
December 2, 2011
- Pfizer President Umeda Says Steady Performance for Lyrica, “Business Objectives Achieved”
December 2, 2011
- Bayer, Regeneron Initiate PIII Trial for VEGF Trap-Eye in China
December 2, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 2, 2011
- Nippon Shinyaku to Open Representative Office in Beijing
December 2, 2011
- DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
December 2, 2011
- Confusion Seen Temporarily Over FDA Approval for Lipitor Generic
December 2, 2011
- Generic Drug Makers to Continue Launching Generics of Major Drugs Even with 60% Rule
December 2, 2011
- Teva Receives Tentative Approval for Generic Lipitor in the US
December 2, 2011
- Fuji-Keizai Sees Domestic Biopharamaceutical Market Reaching Nearly ¥1 Trillion in 2015
December 1, 2011
- UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
- Sandoz Files Application for Additional Indication, Dosage, Administration for Anticancer Drug Paclitaxel Based on Data in Public Domain
December 1, 2011
- I'rom HD Sells All I'rom Pharmaceutical Shares to Kyowa Pharmaceutical Industry
December 1, 2011
ページ
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
